Signifor® LAR (pasireotide) Injectable Suspension

Signifor LAR is covered for FDA‑approved acromegaly and Cushing's disease and for specified off‑label compendial uses (Cushing's patients awaiting surgery or awaiting response after radiotherapy) but excluded for non‑compendial/unlisted uses or when required safety/clinical documentation is missing. Coverage requires endocrinologist or Cushing specialist prescription/consultation, documented diagnosis and prior treatments or surgical candidacy (or tumor‑related effects for acromegaly), baseline labs (age‑/sex‑adjusted IGF‑1 for acromegaly; 24‑hr urinary free cortisol for Cushing's), adherence to dosing limits (acromegaly: start 40 mg IM q4w, up to 60 mg if needed; Cushing's: start 10 mg IM q4w, up to 40 mg after 4 months) and specified approval durations (4 months for awaiting surgery/radiotherapy response; 12 months for other approvals) with objective response evidence required for continuation.

"Acromegaly in individuals who have had an inadequate response to surgery and/or for whom surgery is not an option"